Generex Biotechnology Announces First Patient Enrolled in the Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (KeytrudaÒ) for the Treatment of Triple Negative Breast Cancer


You May Also Like

GCC $1.83 Billion In-Vitro Diagnostic Devices Market to 2023

Dublin, Jan. 21, 2019 (GLOBE NEWSWIRE) -- The "GCC In-Vitro Diagnostic Devices Market: Industry ...